Online inquiry

IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7569MR)

This product GTTS-WQ7569MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GPC3 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164617.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2719
UniProt ID P51654
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7569MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9739MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ7218MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ5678MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ3082MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ14021MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ1861MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ3717MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ1462MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW